0000849636 false 0000849636 2023-02-27 2023-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 27, 2023

 

RESPIRERX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   1-16467   33-0303583

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S Employer

Identification No.)

 

126 Valley Road, Suite C

Glen Rock, New Jersey

   07452
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 444-4947

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On February 27, 2023, ResolutionRx Ltd (“ResolutionRx”), an unlisted public Australian Company (Australian Company Number or ACN: 664 925 651, Australian Business Number or ABN: 17 664 925 651) and a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx”) entered into a Services Agreement (“Agreement”) with iNGENu CRO Pty Ltd (Australian Company Number or ACN: 656 400 056) (“iNGENu”) for clinical research and other related services. Under the Agreement, ResolutionRx will be required to make a US$50,000 deposit with iNGENu within 30 days of the rendering of the first invoice by iNGENu which invoice is anticipated to be received within a few days of the signing of the Agreement. The deposit is to be applied to the final research and development budget of approximately US$16.5 million, which has been agreed by the parties and which deposit shall be credited against the first invoice. Under the Agreement, iNGENu is expected to provide full-service contract research organization (“CRO”) clinical and related services, including regulatory, compliance, GMP (good manufacturing practices) manufacturing services in addition to human pharmacokinetic, pharmacodynamic and pivotal human efficacy and safety studies of dronabinol for the treatment of obstructive sleep apnea.

 

The press release dated March 1, 2023 announcing the entry by ResolutionRx into the Agreement, is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

A partially redacted copy of the ResolutionRx and iNGENu CRO Agreement is attached as Exhibit 99.2 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which follows, and is incorporated herein by reference.

 

 
 

 

EXHIBIT INDEX

 

Exhibit Number   Exhibit Description
99.1*   Press Release dated March 1, 2023
99.2*   ResolutionRx Ltd and iNGENu CRO Pty Ltd Services Agreement dated 27 Februay 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Furnished herewith.

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 1, 2023 RESPIRERX PHARMACEUTICALS INC.
  (Registrant)
   
  By: /s/ Jeff E. Margolis      
    Jeff E. Margolis
    SVP, CFO, Secretary and Treasurer

 

 

 

RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos RespireRx Pharmaceuticals (CE).
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos RespireRx Pharmaceuticals (CE).